Premium
Mitogen‐Activated Protein Kinase Phosphatase 1 as an Inflammatory Factor and Drug Target
Author(s) -
Korhonen Riku,
Moilanen Eeva
Publication year - 2014
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12141
Subject(s) - kinase , phosphatase , protein kinase a , mapk/erk pathway , immune system , phosphorylation , innate immune system , signal transduction , regulator , inflammation , biology , microbiology and biotechnology , mitogen activated protein kinase , immunology , biochemistry , gene
Mitogen‐activated protein kinases ( MAPK s) are signaling proteins that are activated through phosphorylation, and they regulate many physiological and pathophysiological processes in cells. Mitogen‐activated protein kinase phosphatase 1 ( MKP ‐1) is an inducible nuclear phosphatase that dephosphorylates MAPK s, and thus, it is a negative feedback regulator of MAPK activity. MKP ‐1 has been found as a key endogenous suppressor of innate immune responses, as well as a regulator of the onset and course of adaptive immune responses. Altered MKP ‐1 signaling is implicated in chronic inflammatory diseases in man. Interestingly, MKP ‐1 expression and protein function have been found to be regulated by certain anti‐inflammatory drugs, namely by glucocorticoids, antirheumatic gold compounds and PDE 4 inhibitors, and MKP ‐1 has been shown to mediate many of their anti‐inflammatory effects. In this Mini Review, we summarize the effect of MKP ‐1 in the regulation of innate and adaptive immune responses and its role as a potential anti‐inflammatory drug target and review recent findings concerning the role of MKP ‐1 in certain anti‐inflammatory drug effects.